Seelos Encouraging Data from In Vivo Study of SLS-005 in Aggressive Preclinical Model of Alzheimer's

  Treatment with SLS-005 demonstrated a 46% reduction in tau protein and an 18% reduction in NfL biomarker from baseline values within six months  

- Seelos has been selected to present these data at Neuroscience 2023 to be held on November 11-15, 2023 in Washington, D.C. 

https://www.biospace.com/article/releases/seelos-therapeutics-announces-encouraging-data-from-an-in-vivo-study-of-sls-005-in-an-aggressive-preclinical-model-of-alzheimer-s-disease/